GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunflower Pharmaceutical Group Co Ltd (SZSE:002737) » Definitions » EV-to-EBIT

Sunflower Pharmaceutical Group Co (SZSE:002737) EV-to-EBIT : 8.34 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sunflower Pharmaceutical Group Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sunflower Pharmaceutical Group Co's Enterprise Value is ¥12,120 Mil. Sunflower Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ¥1,454 Mil. Therefore, Sunflower Pharmaceutical Group Co's EV-to-EBIT for today is 8.34.

The historical rank and industry rank for Sunflower Pharmaceutical Group Co's EV-to-EBIT or its related term are showing as below:

SZSE:002737' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.59   Med: 10.67   Max: 33.28
Current: 8.34

During the past 12 years, the highest EV-to-EBIT of Sunflower Pharmaceutical Group Co was 33.28. The lowest was 6.59. And the median was 10.67.

SZSE:002737's EV-to-EBIT is ranked better than
77.54% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs SZSE:002737: 8.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sunflower Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Sep. 2023 was ¥11,726 Mil. Sunflower Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ¥1,454 Mil. Sunflower Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 12.40%.


Sunflower Pharmaceutical Group Co EV-to-EBIT Historical Data

The historical data trend for Sunflower Pharmaceutical Group Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunflower Pharmaceutical Group Co EV-to-EBIT Chart

Sunflower Pharmaceutical Group Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.34 9.59 9.43 8.95 9.50

Sunflower Pharmaceutical Group Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.81 9.50 7.19 8.23 8.07

Competitive Comparison of Sunflower Pharmaceutical Group Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sunflower Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunflower Pharmaceutical Group Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunflower Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunflower Pharmaceutical Group Co's EV-to-EBIT falls into.



Sunflower Pharmaceutical Group Co EV-to-EBIT Calculation

Sunflower Pharmaceutical Group Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12119.543/1453.817
=8.34

Sunflower Pharmaceutical Group Co's current Enterprise Value is ¥12,120 Mil.
Sunflower Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunflower Pharmaceutical Group Co  (SZSE:002737) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sunflower Pharmaceutical Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=1453.817/11726.142
=12.40 %

Sunflower Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Sep. 2023 was ¥11,726 Mil.
Sunflower Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunflower Pharmaceutical Group Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sunflower Pharmaceutical Group Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunflower Pharmaceutical Group Co (SZSE:002737) Business Description

Traded in Other Exchanges
N/A
Address
Welcome Road, 18 East Lake Road, Harbin High-Tech Industrial Development Zone, Harbin, Heilongjiang, CHN
Sunflower Pharmaceutical Group Co Ltd is engaged in pharmaceutical manufacturing, marketing, and scientific research. The company's product profile include Honeysuckle, Weikangling Granules, Autumn pear moisturizing cream, Vitamin AD drops, Pediatric paracetamol granules, Jianweixiaoshi tablets, Pediatric Chai Gui Antipyretic Granules, Pediatric cough syrup, Kang Fu anti-inflammatory suppository, Xiangsha Yangwei Pills, and others.

Sunflower Pharmaceutical Group Co (SZSE:002737) Headlines

No Headlines